Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Cancer drug approvals and setbacks in 2023

Nature Cancer volume 4, pages 1612–1614 (2023)Cite this article

Bispecific T cell engagers and antibody–drug conjugates took center stage in a year that also brought several new kinds of small-molecule therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bargou, R. C. Nat. Cancer 4, 1054–1055 (2023).

    Article  CAS  PubMed  Google Scholar 

  2. Firestone, R., Lesokhin, A. M. & Usmani, S. Z. Blood Cancer Discov. 4, 433–436 (2023).

    Article  PubMed  Google Scholar 

  3. Eisenstein, M. Nature 621, S8–S11 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Dolgin, E. Nat. Rev. Drug Discov. 22, 607–609 (2023).

    Article  CAS  PubMed  Google Scholar 

  5. Rojas, L. A. et al. Nature 618, 144–150 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sacher, A. et al. N. Engl. J. Med. 389, 710–721 (2023).

    Article  CAS  PubMed  Google Scholar 

  7. Mullard, A. Nat. Rev. Drug Discov. https://doi.org/10.1038/d41573-023-00169-8 (2023).

    Article  PubMed  Google Scholar 

  8. Shitara, K. et al. Lancet 401, 1655–1668 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Mullard, A. Nat. Rev. Drug Discov. 22, 683–686 (2023).

    Article  CAS  PubMed  Google Scholar 

  10. Cancer Discov. 13, 1032–1033 (2023).

  11. Mato, A. R. et al. N. Engl. J. Med. 389, 33–44 (2023).

    Article  CAS  PubMed  Google Scholar 

  12. Turner, N. C. et al. New Engl. J. Med. 388, 2058–2070 (2023).

    Article  CAS  PubMed  Google Scholar 

  13. Patel, R. et al. npj Breast Cancer 9, 20 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kluetz, P. G. et al. Clin. Cancer Res. 27, 916–921 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Science journalist, Somerville, MA, USA

    Elie Dolgin

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elie Dolgin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Cancer drug approvals and setbacks in 2023. Nat Cancer 4, 1612–1614 (2023). https://doi.org/10.1038/s43018-023-00683-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00683-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing